undamentalytics Newsletter
Sign in

Verastem, Inc. key statistics and ratios

In fiscal 2025, Verastem, Inc. had an operating margin of -550.3%, debt equal to 133.5% of equity and a current ratio of 3.09. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222024Dec 20242025Dec 2025LTMJun 2026
Gross margin99.4%———————
Operating margin−354.8%−758.1%−55.8%<−999%<−999%<−999%−550.3%−182.6%
Net margin−271.1%−854.8%−76.5%<−999%<−999%<−999%−677.6%−231.6%
Free-cash-flow margin−284.5%−793.6%−37.9%<−999%—<−999%−444.8%−185.3%
Return on equity−58.3%—−110.6%−70.2%−109.4%———
Return on assets−26.1%−70.7%−45.2%−54.1%−72.5%−132.9%−120.4%−89.5%
Asset turnover0.100.080.590.020.030.100.180.39
Current ratio6.832.848.485.694.293.073.092.25
Debt to equity76.6%955.6%16.5%0.3%52.8%—133.5%148.0%
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/mn/mn/mn/m
R&D as % of revenue163.4%262.2%46.7%>999%>999%813.3%370.7%160.2%
SG&A as % of revenue289.2%579.8%70.9%>999%962.1%436.2%262.5%108.7%
Capital spending as % of revenue5.6%0.0%0.0%9.5%—0.3%0.0%0.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $207m
Short-term assets $176mLonger-term assets $30m
What it owes, and who funded it · $207m
Short-term liabilities $78mLonger-term liabilities $78mShareholders' equity $50m
  • Short-term assets cover short-term liabilities $176m of assets due within a year against $78m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $176m short-term assets against $78m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$160m against $1m of interest.

From Verastem, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

28 /100

Weak moat

How hard Verastem's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -69.9% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -486.2%; its worst year was -2218.9%.

  • Discipline 10 / 20

    The diluted share count fell 94.4% over five years; stock-based pay has been a median 28.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (33 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BCYC vs VSTMFDMT vs VSTMPLX vs VSTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Verastem, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Verastem, Inc.